5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, and innovative drug trends
To assess the impact of pharmaceutical policy and market dynamics on market access, GlobalData has conducted a comparative analysis of …
Post
-
-
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines
HLS Therapeutics has signed an agreement with Esperion Therapeutics for in-licensing and commercialising the oral cardiovascular medicines, Nexletol (bempedoic acid) …
-
Bavarian Nordic shares rise 7% following strong Q1 for vaccine sales
Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from the same period in 2024. The …
-
NewBiologix licenses cell line technology to Recipharm Advanced Bio
Swiss biotechnology company NewBiologix has given a non-exclusive technology licence to Recipharm Advanced Bio to provide biotech and pharma companies …
-
FDA chief Martin Makary sets June deadline for genAI rollout
The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement generative artificial intelligence (genAI) across the …
-
Haya secures $65m in Series A funds to advance heart failure treatment
Haya Therapeutics has procured $65m in Series A funding to expedite the clinical development of HTX-001 for treating heart failure. The …
-
Sanofi exec tells biotechs not to scrimp on clinical trial design
At a time when the biotech sector has been struggling with a lack of investment, some companies have had to …
-
Viralgen and Trogenix to progress gene therapy for glioblastoma
Contract development and manufacturing organisation (CDMO) Viralgen has partnered biotech company Trogenix to accelerate the development of a recombinant adeno-associated …
-
VC firm Vivo Capital outlays $740m for biotech investment
Set against a backdrop of barren biotech investment, Vivo Capital has secured $740m to back preclinical and clinical-stage life science …
-
BioVaxys and Sona partner to develop cancer therapeutics
BioVaxys Technology and Sona Nanotech have signed a research agreement to develop cancer therapeutics utilising the former’s DPX immune educating …
-
ARS Pharma’s epinephrine nasal spray 1mg now available in US
ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray) 1mg in the US, providing a new option for …
-
FDA plans to expand unannounced inspections of foreign drug plants
The US Food and Drug Administration (FDA) is moving to tighten oversight of foreign manufacturers supplying the US market by …
-
European biotechs must understand US culture while seeking funding
At a time when the US is becoming more self-focused, European biotechs must understand and appreciate US culture when seeking …
-
FDA grants RMAT status to Opus Genetics’ OPGx-LCA5 gene therapy
The US Food and Drug Administration (FDA) has awarded a regenerative medicine advanced therapy (RMAT) designation to Opus Genetics’ gene …
-
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster …
